Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Change in Cash (2017 - 2025)

Historic Change in Cash for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to $42.7 million.

  • Dianthus Therapeutics' Change in Cash rose 11522.57% to $42.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.3 million, marking a year-over-year increase of 11802.47%. This contributed to the annual value of -$109.4 million for FY2024, which is 19350.5% down from last year.
  • Dianthus Therapeutics' Change in Cash amounted to $42.7 million in Q3 2025, which was up 11522.57% from $3.1 million recorded in Q2 2025.
  • Dianthus Therapeutics' Change in Cash's 5-year high stood at $197.4 million during Q1 2024, with a 5-year trough of -$280.3 million in Q3 2024.
  • Its 4-year average for Change in Cash is $3.2 million, with a median of -$10.9 million in 2024.
  • Examining YoY changes over the last 5 years, Dianthus Therapeutics' Change in Cash showed a top increase of 241559.83% in 2024 and a maximum decrease of 33972.14% in 2024.
  • Over the past 4 years, Dianthus Therapeutics' Change in Cash (Quarter) stood at -$21.5 million in 2022, then decreased by 15.99% to -$25.0 million in 2023, then soared by 56.41% to -$10.9 million in 2024, then soared by 492.38% to $42.7 million in 2025.
  • Its Change in Cash was $42.7 million in Q3 2025, compared to $3.1 million in Q2 2025 and -$12.7 million in Q1 2025.